Treatment for EGFR-Positive Non-Small Cell Lung Cancer

First-Line Treatment Options

The National Comprehensive Cancer Network recommends osimertinib as the preferred first-line treatment for patients with advanced or metastatic NSCLC with EGFR-activating mutations due to superior efficacy and safety compared to other EGFR TKIs 1, 2
Osimertinib is the preferred first-line therapy for patients with EGFR exon 19 deletion or exon 21 L858R mutations due to superior progression-free survival and overall survival compared to first-generation EGFR TKIs 3, 2
Osimertinib demonstrates better blood-brain barrier penetration with CNS response rates >60%, making it particularly beneficial for patients with brain metastases 3
Other FDA-approved first-line options include erlotinib, gefitinib, afatinib, and dacomitinib (all category 1 recommendations) 1, 2

The National Comprehensive Cancer Network suggests that all EGFR TKIs are appropriate for patients with performance status 0-4 1, 4
Osimertinib is preferred for patients with brain metastases due to superior CNS penetration 3, 1
Second-generation TKIs (afatinib, dacomitinib) are associated with more toxicities leading to dose reductions 3

For patients with symptomatic systemic progression after osimertinib, amivantamab-vmjw plus carboplatin and pemetrexed is the preferred option (category 1) for patients with multiple lesions (nonsquamous histology) 1, 2
Rebiopsy is recommended to rule out transformation to small cell histology (occurs in ~5% of EGFR TKI-resistant tumors) 1

For oligometastatic disease (1-3 metastases), consider definitive local therapy (stereotactic ablative radiotherapy or surgery) as consolidation after systemic therapy 1, 5
Avoid PD-1/PD-L1 inhibitor monotherapy in EGFR-positive NSCLC as it shows inferior efficacy regardless of PD-L1 expression 1, 2
Be cautious when using EGFR TKIs in combination with or following immune checkpoint inhibitors due to potential for increased adverse events, particularly pneumonitis 1

The National Comprehensive Cancer Network (NCCN) 2024 guidelines recommend osimertinib plus pemetrexed and platinum as a Category 1 "other recommended" first-line option for nonsquamous EGFR-mutated NSCLC 6, 7
The NCCN guidelines suggest that patients with CNS metastases at baseline may benefit from combination therapy, with a median PFS of 24.9 months with combination versus 13.8 months with osimertinib alone 8
Patients with L858R exon 21 mutations may also benefit from combination therapy, with a median PFS of 24.7 months with combination versus 13.9 months with osimertinib alone 8
The American College of Clinical Oncology recommends considering combination therapy for patients with high disease burden or multiple metastatic sites 9

The combination of osimertinib with chemotherapy increases grade ≥3 adverse events (64-70% vs 27-34% with monotherapy), primarily driven by chemotherapy-related toxicities including neutropenia, thrombocytopenia, and anemia 6

For patients with symptomatic systemic progression and multiple lesions after osimertinib, the NCCN recommends amivantamab plus carboplatin and pemetrexed as a Category 1 preferred option (nonsquamous histology) 10
The median PFS with amivantamab plus chemotherapy is 6.3 months versus 4.2 months with chemotherapy alone (HR 0.48, P <.001) 7, 8
The objective response rate with amivantamab plus chemotherapy is 64% versus 36% 7

The NCCN guidelines advise against using PD-1/PD-L1 inhibitors in EGFR-mutated NSCLC, as they show inferior efficacy regardless of PD-L1 expression 6
The guidelines also recommend avoiding osimertinib within 3 months of immune checkpoint inhibitors, as the risk of pneumonitis is significantly increased 6, 7